fbpx

National uniformity for pharmacists administering medicines

6 September 2024

 

The Pharmaceutical Society of Australia (PSA) has welcomed confirmation by the South Australian Office of the Chief Pharmacist (OCP) that pharmacists in South Australia can administer medicines to their patients. This marks an important milestone in establishing national consistency in pharmacists’ scope of practice, enabling pharmacists to administer medicines across all Australian states and territories. It also empowers pharmacists to continue delivering essential healthcare services to their communities.

 

Dr Manya Angley FPS, PSA SA/NT President, welcomed the confirmation by the OCP, noting that it brings the nation one step closer to a more accessible, patient-centred healthcare system.

 

“This is a significant outcome for patients and pharmacists,” said Dr Angley. “By enabling pharmacists in South Australia to administer medicines, we are providing more opportunities for patients to access timely care and improve health outcomes, bringing our scope in line with other jurisdictions.”

 

“Confirmation by the OCP that pharmacists in SA can administer medicines aligns with PSA’s visionary roadmap for the future of pharmacy practice in Australia in Pharmacists in 2030, which advocates for legislative and practice changes to allow pharmacists to prescribe and administer a greater range of medicines.”

 

“Pharmacists are highly trained and trusted healthcare professionals, and we are ready to fulfil these expanded responsibilities,” said PSA National President, Associate Professor Fei Sim FPS. “We call on governments to continue working with the profession and take active steps to enable necessary changes to be implemented, ultimately improving patient access to care whilst maintaining standards, professionalism and quality.”

 

PSA has a range of educational resources available for pharmacists wishing to build their competence in administering medicines, including the Administering Medicines by Injection Course and Guidelines for pharmacists administering medicines by injection.

 

As part of the long-term vision for improving access to medicines and reducing pressure on the healthcare system, PSA remains committed to advocating for further enhancements to pharmacists’ scope of practice.

 

PSA’s recently launched Pharmacists in 2030 vision can be found here: www.psa.org.au/advocacy/working-for-our-profession/pharmacists_in_2030/

New South Wales expands the role of community pharmacists

6 September 2024 

The Pharmaceutical Society of Australia (PSA) welcomes the announcement from New South Wales Health Minister Ryan Park, improving access to medicines through the expansion of pharmacists’ scope of practice in NSW.

The NSW Government will enable pharmacists to provide treatment for a broader range of common and mild conditions, including ear infections, nausea and vomiting, reflux, acne, muscle pain and wound management.

PSA NSW President Luke Kelly FPS welcomed the decision which will allow pharmacists to improve access to healthcare across the state.

“PSA has long advocated for expanding pharmacists’ scope of practice in NSW, and we are grateful for the trust placed in pharmacists by the NSW Government following the success of the NSW Pharmacy Trial,” Mr Kelly said

“It is encouraging to see pharmacists’ accessibility and skills leveraged to provide NSW residents with more timely and accessible health care for a broader range of conditions. This will make our health system more efficient and safer.’’

“The recognition of Queensland trained pharmacists being able to offer these services in NSW is a positive step. National harmonisation of training requirements will cut red tape and enable more pharmacists to deliver essential services to their communities.”

“PSA will continue to work collaboratively with Minister Park and the NSW Government to ensure these services are implemented professionally, effectively and safely.” he said.

PSA National President, Associate Professor Fei Sim FPS commended the NSW Government for recognising pharmacists’ expertise as pharmacists continue to play a vital role in supporting community health.

“PSA supports improving timely and equitable access to care for all Australians through the expansion of prescribing by pharmacists in a rigorous, robust and responsible manner,” said A/Prof Sim.

 

“PSA remains committed to preparing the workforce by providing training, education, and practice support to upskill pharmacists, ensuring they are equipped to deliver these services effectively.”

“This announcement follows the launch of Pharmacists in 2030, PSA’s vision for the future of pharmacist practice.  Expanding pharmacists’ scope to deliver greater access to healthcare to address unmet health needs is a key step towards realising this vision.”

PSA’s Pharmacists in 2030 vision can be found here: https://www.psa.org.au/advocacy/working-for-our-profession/pharmacists_in_2030/ 

International Overdose Awareness Day: Addressing the Emergence of Nitazines and Enhancing Access to Naloxone through Pharmacies

30 August 2024

 

As International Overdose Awareness Day on 31 August approaches, it is a reminder of the critical importance of raising awareness about overdose prevention, reducing stigma around drug-related deaths and acknowledging the loss of families affected by substance use disorder.

This year the focus of pharmacists extends to new and emerging challenges, including the emergence of nitazines in Australia and the continued efforts to expand life-saving measures, such as the Take Home Naloxone program.

Emergence of Nitazines in Australia

In recent months, there has been an increase in the detection of nitazines in Australia.

Nitazines are a group of synthetic opioids which are significantly more potent than fentanyl, posing a heightened risk of overdose and death. Nitazines have been found in a variety of illicit drugs, including non-opioid substances, and in many cases, people have unknowingly consumed them.

The introduction of nitazines has been noted in several reports and the threat they pose underscores the need for increased vigilance, public education and proactive measures to prevent overdoses.

Take Home Naloxone Program: A Life-Saving Initiative

The federal Government has expanded the Take Home Naloxone program, fully funding the availability of naloxone and ensuring there are no out-of-pocket costs for people who may experience  or witness an overdose.

This initiative is a critical step in reducing overdose deaths, ensuring that individuals at risk of opioid overdose, their friends and family members have ready access to this life-saving medication.

 

Community pharmacists play a vital role in the program’s success, serving as accessible points for the distribution of naloxone. However, only around two thirds of Australian pharmacies are currently stocking this critical medicine.

By increasing access to naloxone, more Australians can be empowered to respond effectively in the event of an overdose, potentially saving countless lives.

New resources to assist pharmacists in conversations about opioid use and medicines safety are available at www.psa.org.au/opioidsafety.

Drug Checking – an opportunity to do more

In addition to promoting overdose prevention through naloxone access, the Pharmaceutical Society of Australia (PSA) continues to advocate for the implementation of drug checking services across Australia.

PSA first published a position on drug checking in 2019 and continues to support advocacy for regulation review.

PSA supports the introduction of drug checking to further enhance public health and safety, especially because new and dangerous substances like nitazines have entered the market.

Raising Further Awareness

PSA’s recently released vision for the profession, Pharmacists in 2030, articulates six actions to realise the vision. One key action is Access to Care, supporting pharmacists to provide all consumers greater access to care by increasing and leveraging their accessibility to address unmet health needs.

 

PSA President, Associate Professor Fei Sim, said “Pharmacists, as medicine experts, are essential in mitigating the risk of overdose linked to both medicines and illicit substances. Whether it is participation in the Take Home Naloxone program or actively contributing to opioid stewardship and improved quality use of medicines, pharmacists’ vital role and contribution in community pharmacies, hospitals, aged care facilities, and other primary care areas should not be overlooked.”

“International Overdose Awareness Day presents an opportunity for the community, healthcare professionals, policymakers and the media to continue raising awareness about the risks of opioid overdose, the emergence of new threats, such as nitazines, and the importance of harm reduction strategies.”

“PSA encourages support for initiatives including the Take Home Naloxone program and the adoption of drug checking services, which are vital to efforts to save lives and reduce the impact of drug-related harm.”

 

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030

PSA congratulates Lia Finocchiaro and the Country Liberal Party on their election in the Northern Territory

30 August 2024

The Pharmaceutical Society of Australia (PSA) warmly congratulates Hon Lia Finocchiaro MLA and the Country Liberal Party (CLP) on being elected to government in the Northern Territory.

PSA welcomes the CLP’s plan to expand pharmacy services in the community through the Pharmacy Scope of Practice program, which will offer additional health services for up to 21 conditions.

 

PSA also applauds the incoming government’s commitment to implement pharmacist prescribing for uncomplicated Urinary Tract Infections (UTIs) in women, within the first 100 days of government, bringing the Northern Territory in line with other Australian jurisdictions.

​PSA Northern Territory and South Australia Vice President Colleen Niland MPS welcomed the commitment, and encouraged pharmacists to pursue the appropriate training, equipping them with everything they need to provide these services”

“Empowering pharmacists to prescribe treatment for UTIs improves access to care, improves health outcomes across the Territory, particularly for rural and regional communities where access to healthcare services can be limited,” Ms Niland said.

PSA’s online training program Managing uncomplicated cystitis (Urinary Tract Infection)is available now for pharmacists.

By expanding scope, pharmacists can support primary healthcare services through timely and convenient access with community pharmacists able to treat other conditions like impetigo (school sores), travel health, smoking cessation and more.

PSA is committed to working closely with the NT Government to ensure the program best meets the needs of Territorians and pharmacists have access to the necessary additional training.

PSA National President Associate Professor Fei Sim FPS also welcomed the announcements.

“Allowing pharmacists to practise to their full and top of scope makes efficient use of health resources, benefitting the broader health system.”

“Our health system is under pressure. The time is now to look at innovative models of care where the skillsets of all health professionals, including pharmacists, can be fully utilised to build overall health system capacity as we continue to support our population’s health.

​PSA National President, Associate Professor Fei Sim FPS is encouraging pharmacists to undertake training in anticipation of their expanding roles.

​“Throughout scope expansion across the country, whether it is assessment and prescribing for management of UTIs, oral contraception or other acute and chronic condition management programs, PSA has been supporting pharmacists along the way,” Associate Professor Sim said.

“PSA is committed to focusing on workforce preparation, including training, education, practice support and upskilling of pharmacists to undertake and deliver these services.

“PSA looks forward to working with the NT Government as part of a collaborative approach to workforce preparation.”

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030 

Pharmacists encouraged to Wear it Purple and provide safe, inclusive care

30 August 2024

The Pharmaceutical Society of Australia (PSA) is proud to support Wear It Purple Day and stand in solidarity with LGBTQIA+ youth.

Wear It Purple Day was founded in 2010 in response to LGBTQIA+ youth taking their own lives following bullying and harassment resulting from a lack of acceptance of their sexuality or gender identity. The day strives to foster supportive, safe, empowering and inclusive environments for rainbow young people.

Mental health and wellbeing outcomes of LGBTQIA+ people in Australia remain a concern with rates of diagnosed depression 6 times higher than the general population. Rates of suicide attempts are 5 times higher for LGBTQIA+ young people, while young transgender people are 15 times more likely to have a suicide attempt than the general population. These statistics bring sharply into focus the importance of providing safe and inclusive healthcare for rainbow young people.

PSA is partnering with The University of Queensland (UQ) to foster inclusive and empowered primary care workforces through the Promoting queer-inclusive professional identities for diversity in primary healthcare (PRIDE co-design) project.

As a PRIDE project partner, PSA will offer education and resources to help pharmacists improve the care they provide LGBTQIA+ patients.

PSA’s recently released vision for the profession, Pharmacists in 2030, articulates six actions to realise the vision. One key action is Equity, supporting pharmacists to meet the unique needs of vulnerable individuals and priority populations to address the disparity of health status through the provision of appropriate and responsive care.

PSA National President Associate Professor Fei Sim FPS said there is still a long way to go to addressing health inequalities for LGBTQIA+ Australians.

“Everyone has the right to safe, affirming health care,” Associate Professor Sim said.

“PSA is committed to empower all pharmacists, through education and professional development, to provide culturally appropriate care to all population groups.

“As some of the most accessible health care professionals, pharmacists have a duty of care to patients to ensure that healthcare is provided in a way that is inclusive and appropriate for all people.

“We have an enormous opportunity to improve these confronting statistics and ensure that young people feel safe and supported seeking mental and physical health support.

“PSA wants to ensure all pharmacists have the confidence and knowledge to deliver safe and equitable health care.

“I challenge pharmacists to embrace the resources and training available through the PRIDE project to ensure they deliver inclusive and affirming models of care for LGBTQIA+ people in our communities.’

PRIDE Project leader and Chief Investigator Dr Megan Ross highlighted the importance of creating a culture of safe and supportive environments for LGBTQIA+ people.

“Building the capacity of the primary health workforce to deliver safe and affirming care addresses a current gap in primary care.

“Over half of LGBTQIA+ Australians have reported discrimination due to their sexual orientation, and almost 80% of people who are trans or gender diverse have experienced discrimination due to their gender identity. Stigma and discrimination in the health care context can lead to delaying or avoiding healthcare entirely which contributes to greater health disparities experienced by LGBTQIA+ communities.

“A multi-disciplinary affirming provider network will facilitate access to continuous, trustable safe and affirming care across the primary care landscape for LGBTQIA+ consumers, and we are proud to partner with PSA on the PRIDE project initiative.”

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030

PSA Calls for the removal of vaccination red tape

20 August 2024 

 

The Pharmaceutical Society of Australia (PSA) is calling for the removal of vaccination red tape and for national harmonisation of pharmacist vaccination scope to ensure all Australians have equitable access to vaccination services.

 

The Australian Immunisation Handbook serves as the national vaccination formulary. Pharmacists, along with all Australian healthcare professionals who are immunisers, should adopt this as the national standard for defining vaccine formularies, instead of relying on complex regulatory instruments unique to each state and territory.

Regardless of location, everyone should have access to the same vaccine formulary at their community pharmacy.  Vaccines should be as accessible as possible to those who need them most, at a time and place of their choosing.

Reducing barriers to vaccination uptake should be a priority to improve equity and access to the health care system. Australians are increasingly turning to pharmacists for vaccinations. Empowering pharmacists to provide this essential service, in a consistent manner across jurisdictions, will be key to reaching the immunisation target in Australia.

The approval of a vaccine to protect Australians against the highly infectious respiratory syncytial virus (RSV) is a valuable addition to the vaccines available in community pharmacies. Residents of South Australia, Western Australia, and the Northern Territory would welcome the availability of the RSV vaccine at their local pharmacies, as is the case in other all jurisdictions across the country.

Pharmacists in 2030 is the PSA’s vision for the future of the pharmacy profession and outlines a road map demonstrating how pharmacists can reach their full potential over the next 6 years, ultimately improving quality use of medicines and medicines stewardship and Australians’ access to care in an equitable, consistent and sustainable manner.  Removing regulations that prevent pharmacists from administering all vaccines to all at risk Australians would be a crucial first step towards realising this vision.

 

Quotes attributed to PSA National President, Associate Professor Fei Sim 

“Pharmacists are underutilised in many states and territories, with regulatory barriers preventing them from practising to their full potential when providing vaccination services.”

“Pharmacists have demonstrated competency in delivering vaccines safely and effectively. Leveraging the accessibility of pharmacists to administer a greater range of vaccines would significantly improve uptake and reduce hospitalisations from vaccine preventable diseases.”

“Allowing pharmacists to deliver childhood vaccinations, including influenza vaccines, provides Australians with greater choice and equitable access to vaccines.”

“Allowing pharmacists to practise to the top of their scope makes efficient use of health resources, benefitting the broader health system.”

“With the Continuing Professional Development cycle for pharmacists ending on 30 September, I encourage all pharmacist immunisers to visit PSA Vaccination Education Hub to help you meet your professional requirements and maintain competence in vaccination services.”

“PSA offers a variety of immunisation educational resources for pharmacists, including the Respiratory syncytial virus (RSV) module and the Vaccination Webinar Series.  The next webinar in this series focuses on promoting pharmacy vaccination services, particularly for adolescents who missed HPV (Human Papillomavirus) vaccination due to COVID lockdowns.”

 

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030

Routine Opioid Outcome Monitoring (ROOM) Tool

The Opioid Safety Toolkit also includes the Routine Opioid Outcome Monitoring (ROOM) Tool, a patient-reported outcomes measure designed to help patients and healthcare providers monitor clinical outcomes and identify risk factors associated with opioid use.

 

The ROOM Tool measures six key areas:  Analgesia (pain relief), Activity (functioning), Adverse effects, Addiction-related (or aberrant) behaviours, Affect (mood), and Alcohol (toxicity risk).

 

The ROOM Tool can be completed on paper or online, with a patient version and healthcare provider version available for download below. ROOM can be self-completed independently by the patient or with their pharmacist or prescriber. It takes less than five minutes to complete online (see button below) within the Toolkit, with online completion providing personalised information about outcomes, including identifying unmanaged pain, risks or adverse effects.  Pharmacists can utilise this tool to facilitate patient-centred discussions.

Image of ROOM Tool

Help your patients create an opioid safety plan

Using this online interactive resource, patients can create a personalised opioid safety plan (see button below) which can be shared with family members, carers or household members.  This plan helps patients identify opioid-related risks specific to their circumstances and provides guidance on recognising symptoms and treating opioid toxicity or overdose, including administering naloxone.

 

Naloxone has been shown to reduce opioid-related harms and is recommended for anyone on long-term prescription opioids to have in the home (referred to as ‘take-home naloxone’ – see button below).   Take-home naloxone is available as a nasal spray or intramuscular injection at no charge from many community pharmacies in Australia.  Any pharmacy can stock take-home naloxone, and any pharmacist can supply it without a prescription. You can claim reimbursement for naloxone you supply at https://www.ppaonline.com.au/

Mechanisms facilitating timely access to anticipatory medicines for community palliative patients (palliPHARM).

Palliative Care image - reassuring hands
What did we do?

PSA developed mechanisms that facilitate community patients (in private homes residential aged care facilities) to have timely access to symptom control medicines. 

 

Why did we do it?

To support pharmacists in avoiding unnecessary suffering of patients and unwanted transfers to acute care facilities. 

 

Value to PSA members

The palliPHARM interventions have raised awareness of palliative care needs amongst the pharmacy sector, improving outcomes for community-based palliative patients.

 

Project impact

Coming soon.

Activating pharmacists to reduce medication related problems​ (ACTMed – MRFF)

image of lots of different pills
What did we do?

PSA collaborated with partner organisations to co-design ACTMed (Actionable medication safety dashboard) which incorporates innovative IT solutions and an actionable dashboard to identify serious MRPs.

 

Why did we do it?

The trial sought to develop and implement innovative technology to support pharmacists in their professional practice.  

 

Value to PSA members

The successful development and implementation of this tool and the associated positive health outcomes provide strong evidence for the future investment in digital tools to support pharmacy practice. ​

 

Project impact

Coming soon.